VORIF TABLETS 200mg
VORIF TABLETS (Voriconazole tablets)
VORIF, containing Voriconazole, demonstrates potent antifungal activity by inhibiting fungal cytochrome P-450 enzymes crucial for ergosterol biosynthesis.
Indicated for invasive aspergillosis, esophageal candidiasis, candidemia, and serious fungal infections, VORIF addresses a spectrum of fungal challenges in both adults and children.
The dosage regimen, including a loading dose for the first 24 hours, ensures rapid achievement of therapeutic plasma concentrations. Subsequent maintenance doses vary based on patient weight.
While generally well-tolerated, users should be mindful of potential adverse reactions, including hypokalemia, visual changes, and, rarely, serious events like pancreatitis or Stevens-Johnson syndrome.
VORIF is contraindicated in cases of hypersensitivity to voriconazole components and when co administered with specific drugs like rifampin, ritonavir, and carbamazepine due to potential interactions
VORCAZ TABLET (VORICONAZOLE) 200 mg PACK OF 10 TABLETS
VORCAZ TABLETS (Voriconazole) Tablets J.P 200mg, Product by Daneen Pharma
VORCAZ tablets contain Voriconazole, a broad-spectrum antifungal agent
They are indicated for treating invasive aspergillosis and candidaemia in non-neutropenic patients
Voriconazole has nonlinear pharmacokinetics and should be dosed carefully
Contraindications include hypersensitivity and coadministration with certain drugs
Common side effects include visual impairment, pyrexia, and gastrointestinal symptoms
VORIF TABLETS 50mg
VORIF TABLETS (Voriconazole tablets)
VORIF, containing Voriconazole, demonstrates potent antifungal activity by inhibiting fungal cytochrome P-450 enzymes crucial for ergosterol biosynthesis.
Indicated for invasive aspergillosis, esophageal candidiasis, candidemia, and serious fungal infections, VORIF addresses a spectrum of fungal challenges in both adults and children.
The dosage regimen, including a loading dose for the first 24 hours, ensures rapid achievement of therapeutic plasma concentrations. Subsequent maintenance doses vary based on patient weight.
While generally well-tolerated, users should be mindful of potential adverse reactions, including hypokalemia, visual changes, and, rarely, serious events like pancreatitis or Stevens-Johnson syndrome.
VORIF is contraindicated in cases of hypersensitivity to voriconazole components and when co administered with specific drugs like rifampin, ritonavir, and carbamazepine due to potential interactions